Small Cap Feast

Small Cap Feast – 25 March 2019

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?

Main Market (Premium)

US Solar Fund, a newly-established investment company focused on investing in solar power assets mainly in the US, looking to raise $250m at $1. Expected 16 April


Network International Holdings—Pleading enabler of digital commerce across the Middle East and Africa  region, operating across over 50 highly underpenetrated payment markets that contain a total population of 1.5 bn. 2018 rev $298m, underlying EBITDA $152m.  Due April. No new funds to be raised. Secondary sell down. Targeting 25% of at least 25%.

Techniplas –global  producer and support services company providing highly engineered and technically complex components, making the supply chain to original equipment manufacturers more efficient.  FYDec17 rev $515m.

Breakfast Buffet

Asiamet Resources (ARS.L) 6.8p £66.21m

Updated Mineral Resource Estimate for the Beutong Copper-Gold Project  located in Nagan Raya Regency, Aceh, Indonesia.  Beutong is a large high-quality copper, gold, silver, molybdenum deposit outcropping at surface and remaining open laterally and at depth.

34Mt @ 0.67% Cu, 0.13g/t Au, 1.68g/t Ag and 90ppm Mo in the Measured category

56Mt @ 0.58% Cu, 0.12g/t Au, 2.07/t Ag and 104ppm Mo in the Indicated category

419Mt @ 0.45% Cu, 0.13g/t Au, 1.14/t Ag and 125ppm Mo in the Inferred category

Further drilling campaigns will be directed to growing the deposit well beyond the current Resource envelope, testing the potential for a high grade core at depth, and exploring early stage development options for the project.


Leeds Group (LDSG.L) 20.5p £6.42m

“As noted in our Interim Report, trading performance at our operating subsidiaries has been challenging with increased competition in a reduced market in the first half of the year. Despite this, the Board believed, at that time, that the underlying profit before tax for the full year would be at a higher level than last year.

However, the trading performance of the operating subsidiaries in the second half of the year has been below the Board’s expectations as market conditions have not improved and this is expected to continue for the rest of the financial year. The Group PBT for the full year is therefore expected to be below the Board’s expectations for the current financial year.”

The Group  is totally focused on the import and sale throughout the world of fabric imported chiefly from the Far East.


Grafenia (GRA.L) 12.5p £8.64m

£1.1m subscription at 13.5p. 

“The Board has a clear strategy to accelerate the growth of Grafenia through the acquisition of sign businesses and to open further Nettl Business Superstores. In addition to this, and as noted in the Company’s announcement on 17 Jan 2019, the Board is also investing in its Production Hub at Trafford Park, Manchester.

The Board intends to use the net proceeds of the Subscription for multiple purposes: to relocate and integrate Image Everything’s operations into the Group’s main production hub in Manchester, to invest in the launch of Nettl of America, to make further small acquisitions and for the Group’s general working capital requirements.”

Conrad Bona, non-executive director subscribing to 222,222 shares.


Be Heard (BHRD.L) 1.2p £11.97m

FYDec18 results from the tech, media, data & creative specialists. “Good revenue growth with improved operational efficiencies” .

Group revenue increased by 51% to £29.5m (2017: £19.6m)

Like-for-like revenue growth of +15%

Adjusted EBITDA  increased by 90% to £3m (2017: £1.6m)

Loss from operations £(9.7)m after non-cash impairment charge of goodwill and intangibles of £8.4m and £1.7m of exceptional costs (2017: £(3.9m)). Cash generation improved by £2.4m with cash generated from continuing operation of £0.8m

The new financial year has started positively, against an unsettling market environment and the financial constraints of the Group. Assuming reasonable trading weather ahead, I expect to be able to report positive news as the year progresses.”


Premier Technical Services Group (PTSG.L) 122p £150.9m

The niche specialist services provider, announced new £40m committed facilities together with a £10m accordion with HSBC.

The Group’s turnover and underlying levels of EBITDA have more than trebled since the original facilities were agreed in 2015.  These enlarged facilities, at better margins, provide us with further headroom to allow PTSG to continue to create ongoing shareholder value through organic growth and carefully selected acquisitions.”


Evgen Pharm (EVG.L) 25.5p £20.19m

The clinical stage drug development company focused on the treatment of cancer and neurological conditions, announced positive headline results from the open-label Phase II trial of SFX-01 in 46 patients with estrogen-positive (ER+) metastatic breast cancer. 

Conclusive evidence of anti-cancer activity via objective responses (tumour shrinkage)

24% of patients show a durable clinical benefit for at least 6 months, despite the late stage of disease and patients’ established resistance to hormone therapy

Mild and favourable side effect profile for an anti-cancer drug

Further development of SFX-01 planned for earlier stage patients as an adjunct to a second line hormone therapy to delay onset of resistance.


RA International (RAI.L) 37p £63.36m

The “leading provider of services to remote locations in Africa and the Middle East, announced today that it has signed a Master Service Agreement with IAP Worldwide Services, Inc.

Under the terms of the agreement, RA International will provide supply chain services to IAP on a global scale. The first order issued to RA International is to provide services in sub-Saharan Africa for a total value of up to $8.5m. This order will run until 2023, with services already underway.”


Ovoca Bio (OVB.L) 8p £5.51m

Ovoca Bio plc’s Libicore (BP-101) Meets Primary/Secondary Endpoints in Phase 3 Trial for Hypoactive Sexual Desire Disorder Ahead of Time .

Phase 3 study of Libicore (BP-101) for hypoactive sexual desire disorder (HSDD) in premenopausal women met the pre-specified primary efficacy endpoint of improvement in number of sexually satisfying events:

The pivotal clinical trial, evaluating the efficacy and safety of Libicore (BP-101) versus placebo was stopped early based on the achievement of pre-specified efficacy criteria.

Following these results, Ovoca anticipates filing for approval of Libicore (BP-101) in the Russian Federation, where the clinical program has been conducted to date, in the Q2 of 2019.


Oakley Capital (OCI.L) 200p £404.71m

Acquisition of UNIT4 Business Software Ibérica, S.A. (“Ekon”), a leading Spanish provider of business software. The company generates revenues of c.20m from sales of its integrated software suite, which includes solutions for finance, payroll and CRM, as well as dedicated vertical modules for manufacturing, wholesale, health, retail and construction.  OCI’s indirect contribution through its interest in Fund III, is expected to be approximately £20m.


RedT Energy (RED.L) 1.57p £9.69m

“Further to the announcement made on 14th March, redT energy plc, the energy storage solutions company, announced it has signed heads of terms to partner with Statkraft, Europe’s largest generator of renewable energy, to provide a fully financed ‘solar plus storage’ solution to UK commercial and industrial customers. This is the first time a solar plus storage product, financed under a Power Purchase Agreement model has been offered to the UK market.”


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.